# ADMA Biologics Inc (ADMA) Stock Analysis: Strong Analyst Consensus and 31% Potential Upside

- Link: https://www.directorstalkinterviews.com/adma-biologics-inc-adma-stock-analysis-strong-analyst-consensus-and-31-potential-upside/4121231780
- Published: 2025-12-22T11:37:02+00:00
- Author: Madison Wilson

ADMA Biologics Inc (NASDAQ: ADMA), a biopharmaceutical company specializing in plasma-
derived biologics, is capturing the attention of investors with its robust growth
potential and strong market performance. Currently headquartered in Ramsey, New 
Jersey, ADMA is making significant strides in the healthcare sector by developing
essential treatments for immune deficiencies and infectious diseases.

With a market capitalization of $4.67 billion, ADMA Biologics has demonstrated remarkable
growth, which is reflected in its current stock price of $19.58. The company’s stock
has fluctuated within a 52-week range of $13.99 to $24.51, showcasing its volatility
and the potential for significant gains.

Investors are particularly drawn to ADMA’s forward-looking valuation metrics. While
the trailing P/E ratio and other valuation metrics such as PEG, Price/Book, and 
EV/EBITDA are not available, the forward P/E ratio stands at 20.83, suggesting a
positive outlook for future earnings. The company’s revenue growth of 12% further
underscores its upward trajectory.

ADMA Biologics has a noteworthy Return on Equity (ROE) of 63.17%, highlighting its
efficiency in generating profits from shareholders’ equity. This high ROE, coupled
with a free cash flow of approximately $2.96 million, positions ADMA as a financially
robust company with considerable operational leverage.

From a technical standpoint, the stock is trading above its 50-day moving average
of $16.86 and closely aligns with the 200-day moving average of $18.15. The Relative
Strength Index (RSI) of 43.11 indicates that the stock is neither overbought nor
oversold, providing a stable entry point for potential investors. The MACD and Signal
Line values of 0.72 and 0.92, respectively, further emphasize a neutral to slightly
bullish trend.

Analyst ratings for ADMA are overwhelmingly positive, with three buy ratings and
no hold or sell recommendations. The average target price of $25.67 suggests a potential
upside of 31.09%, making it an attractive investment for those seeking growth opportunities
within the biotech industry. The target price range spans from $17.00 to $30.00,
reflecting a broad consensus on its upside potential.

Despite its promising financial performance and market position, ADMA does not currently
offer dividends, as indicated by a payout ratio of 0.00%. This strategy aligns with
the company’s focus on reinvesting profits to fuel further growth and innovation
in its product offerings.

ADMA Biologics’ success is driven by its portfolio of FDA-approved products, including
BIVIGAM for primary humoral immunodeficiency and Nabi-HB for Hepatitis B exposure.
These treatments, alongside the company’s ongoing development of plasma-derived 
therapeutics, strengthen ADMA’s market presence and potential for future revenue
expansion.

As ADMA continues to innovate and expand its pipeline, investors are advised to 
consider its growth potential, strong analyst consensus, and the substantial upside
indicated by current valuations. With a strategic focus on addressing critical healthcare
needs, ADMA Biologics stands as a compelling opportunity for investors seeking to
capitalize on the dynamic biotech sector.

Share on: